KLRA logo

KAILERA THERAPEUTICS INC

KLRANASDAQ
🏆 #2230 by market capUS Equity
$926.94▼ $52.09 (−5.62%)
Simulated price
🔔
Track KLRA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.6%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.42B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
68
Fair
No chart data available for KLRA.

Trading Snapshot

Day Range
$918.25 – $934.08
52-Week Range
$10.83 – $28.23
Volume
$2.66B
Avg Volume
$2.72B
Shares Outstanding
129.6M
Next Earnings
Nov 9, 2026

Fundamentals Snapshot

Annual Revenue
$166M
Last Q Revenue
$41M
P/E Ratio
-6.2
P/S Ratio
0.0x
EPS (TTM)
$-1.86
Dividend Yield
0.00%

Why Investors Own KLRA

  • ✓High-growth profile — revenue up +38.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 76% gross margin and 15% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KLRA logo

KAILERA THERAPEUTICS INC

KLRA
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$166M▲ +38.9% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
75.6%▲ +3.3% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$41M▲ +38.9% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$24M▲ +38.9% YoY
StockOtter · stockotter.space

About KAILERA THERAPEUTICS INC

Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$1,206.39
▲ +30.1% Upside
High Target$1,493.62
Low Target$1,018.26
Based on 9 analysts

Latest News & Updates

🚀
Barron’s·2h ago

KAILERA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift KLRA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

KAILERA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.